AbbVie & Scripps-based Calibr Moves Novel ‘Switchable’ CAR-T Technology to Phase I Clinical Trial

AbbVie & Scripps-based Calibr Moves Novel ‘Switchable’ CAR-T Technology to Phase I Clinical Trial

The U.S. Food and Drug Administration (FDA) have approved a new Investigational New Drug (IND) application for a novel cell therapy called CLBR001+SWI0I9 leading to an imminent Phase I clinical trial of a new CAR-T technology centering on “switchable” cells that can eliminate life-threatening side-effects that materially impede this powerful class of therapy. The technology has been developed by an elite California research institution.

Sponsored by an interesting partnership bringing together a California research organization associated with Scripps Research called Calibr and multinational biopharma company AbbVie the duo came together in 2018 to develop the drug, affording the Illinois-based company exclusive access to the technology for up to four years the two reported in a press release.

TrialSite News offers a brief breakdown of this situation.

What is the New CAR-T based therapy being tested for?

The sponsors seek to test the therapy on certain blood cancers such as relapsed/refractory B-cell malignancies such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.

Is CLBR001+SWI0I9 Made from a Patient’s own T-cells?

Yes, just like other CAR-T therapi...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee